Relay Therapeutics, Inc. (RLAY) Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Relay Therapeutics, Inc. NASDAQ:RLAY Healthcare · Biotechnology
Mkt Cap $4.02B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
Relay Therapeutics will report third quarter 2026 financial results and corporate highlights after U.S. markets close on Wednesday, November 4, 2026.
The release is a scheduling notice with no results or guidance included; the company's lead asset zovegalisib, a pan-mutant selective PI3Kα inhibitor, is in a Phase 3 trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer.
• 4d ago AI analysis › Press Release
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics announced that management will participate in fireside chats at the 2026 Wells Fargo Healthcare Conference on September 8 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.
Both sessions will be webcast live via the company's investor relations website, with archived replays available for 30 days following the events.
Relay Therapeutics is a clinical-stage precision medicine company focused on cancer and genetic diseases, with its lead asset zovegalisib currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer.
• 2mo ago AI analysis › Press Release ⚠ 3
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics reported Q2 revenue of $0.4 million, down from $0.7 million in the prior year, with a net loss of $83.7 million or $0.41 per share. The company strengthened its balance sheet with approximately $911 million in cash and investments following a $316 million follow-on offering in May, extending its expected runway into 2029.
On the operational front, Relay selected the zovegalisib plus atirmociclib triplet regimen for its front-line breast cancer program and secured a clinical supply agreement with Pfizer. The company also presented initial positive data from the ReInspire trial in vascular anomalies, showing a 60% volumetric response rate at 12 weeks.
Looking ahead, management expects to initiate the Phase 3 front-line breast cancer trial in early 2027, subject to regulatory feedback, with an enrollment update for the ongoing Phase 3 ReDiscover-2 trial anticipated by year-end 2026.
• 2mo ago AI analysis › Press Release
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Relay Therapeutics scheduled the release of its second quarter 2026 financial results and corporate highlights for after the market closes on August 6, 2026.
The company is a clinical-stage precision medicine firm utilizing its Dynamo platform to develop therapies for cancer and genetic diseases, including its lead asset zovegalisib.
Zovegalisib is currently in a Phase 3 clinical trial (ReDiscover-2) for HR+/HER2- metastatic breast cancer and is being investigated for PI3Kα-driven vascular anomalies.
• 3mo ago AI analysis › Press Release
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Relay Therapeutics announced that management will participate in two fireside chats in June.
The sessions are scheduled for the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8.
Webcasts will be available live and archived on the company's investor relations website for 30 days.
• 5mo ago AI analysis › Press Release ● Major
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics priced a public offering of 22.9 million shares at $12.00 per share, raising approximately $275 million in gross proceeds.
The company granted underwriters a 30-day option to purchase up to 3.4 million additional shares. Jefferies, TD Cowen, Goldman Sachs, and Guggenheim acted as joint book-runners.
The capital raise supports the company's clinical-stage pipeline, including its lead asset zovegalisib in Phase 3 trials for breast cancer, but results in significant immediate dilution for existing shareholders.
• 5mo ago AI analysis › Press Release
Relay Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com • 5mo ago Press Release ● Major
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics ended Q1 2026 with $642.1 million in cash and investments, extending its runway into 2029 after raising $137.1 million via at-the-market offerings.
The FDA granted Breakthrough Therapy designation to zovegalisib for 2L PIK3CA-mutant breast cancer, supported by data showing an 11.1-month median PFS in the ReDiscover-2 trial.
Management selected a zovegalisib plus atirmociclib triplet regimen for a planned Phase 3 frontline study launching in early 2027 and initiated a Phase 1/2 trial for its NRAS-selective inhibitor RLY-8161.
• 5mo ago AI analysis › Press Release
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Relay Therapeutics will report its first quarter 2026 financial results and corporate highlights after the U.S. markets close on Tuesday, May 5, 2026.
The announcement serves as a standard notification and includes boilerplate describing the company's Dynamo platform for small molecule precision medicines.
Relay's lead asset, zovegalisib, is currently in a Phase 3 clinical trial for HR+/HER2- metastatic breast cancer and is being investigated for PI3Kα-driven vascular anomalies.
• 6mo ago AI analysis › Press Release ● Major
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Relay Therapeutics reported positive Phase 1/2 data for its zovegalisib triplet combination, showing a 44% objective response rate in heavily pre-treated, median third-line metastatic breast cancer patients.
Based on the tolerability and efficacy profile, the company plans to advance the regimen into a randomized Phase 3 trial for frontline patients, expected to initiate in early 2027.
Pfizer has agreed to supply atirmociclib for the experimental arm and palbociclib for the control arm, while Relay retains full global rights to zovegalisib.
• 6mo ago AI analysis › 
